Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
losartan + alpha lipoic acid
- Development stage
- Phase 2
- Lead developer
- InVasc Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This is a **combination product** containing two active ingredients: **losartan**, an angiotensin II receptor antagonist (ARB) commonly used to treat hypertension and protect renal function, and **alpha lipoic acid**, a small-molecule antioxidant that scavenges free radicals, regenerates endogenous antioxidants, and modulates oxidative stress. Combination of losartan with alpha lipoic acid is under clinical development for the management of diabetic nephropathy and chronic kidney disease, especially in hypertensive diabetic patients, based on evidence suggesting additive or synergistic effects on reducing proteinuria, improving renal biomarkers, and reducing oxidative stress. INV-144 is a clinical-stage candidate based on this combination[4][5]. The mechanism relies on losartan blocking angiotensin II mediated vasoconstriction and organ damage and alpha lipoic acid enhancing antioxidant defense and reducing renal injury.
- Other names
- Losartan Potassium/Lipoic acid
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)NF-κBPPARG (Peroxisome proliferator-activated receptor gamma)
Beyond the preview
Go deeper on losartan + alpha lipoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on losartan + alpha lipoic acid.